Atreca to Present at Two Upcoming Virtual Healthcare Conferences

Rhea-AI Summary

Atreca, a clinical-stage biotechnology company (NASDAQ: BCEL), will present at two upcoming investor conferences. The 2020 Wedbush PacGrow Healthcare Virtual Conference is scheduled for August 12, 2020, at 2:20 p.m. EDT, while the Canaccord Genuity 40th Annual Growth Conference will take place on August 13, 2020, at 4:00 p.m. EDT. Interested investors can access live webcasts through the company's website, with archived replays available for 90 days post-event. Atreca is known for its antibody-based immunotherapeutics and is currently enrolling patients for its Phase 1b study on ATRC-101.

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will participate in two upcoming investor conferences:

2020 Wedbush PacGrow Healthcare Virtual Conference
Wednesday, August 12, 2020
Presentation time: 2:20 p.m. EDT

Canaccord Genuity 40th Annual Growth Conference
Thursday, August 13, 2020
Presentation time: 4:00 p.m. EDT

Live webcasts of each event can be accessed through the Events & Presentations section of the Company's website at ir.atreca.com. Archived replays of the webcasts will be available on the Company's website for 90 days following the live presentations.

About Atreca, Inc.
Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca’s platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.

Contacts
Atreca, Inc.
Herb Cross
Chief Financial Officer
info@atreca.com

Investors:
Alex Gray, 650-779-9251, ext. 251
agray@atreca.com

Media:
Sheryl Seapy, 213-262-9390
sseapy@w2ogroup.com

Source: Atreca, Inc.

FAQ

What is the schedule for Atreca's presentations at investor conferences in August 2020?

Atreca will present at the Wedbush PacGrow Healthcare Virtual Conference on August 12, 2020, at 2:20 p.m. EDT, and at the Canaccord Genuity 40th Annual Growth Conference on August 13, 2020, at 4:00 p.m. EDT.

How can I access the live webcasts of Atreca's investor presentations?

Live webcasts of Atreca's presentations can be accessed through the Events & Presentations section of the company's website.

What is Atreca's lead product candidate?

Atreca's lead product candidate is ATRC-101, which is currently being evaluated in a Phase 1b study for multiple solid tumor cancers.

Where can I find more information about Atreca, Inc.?

More information about Atreca, Inc. can be found on their official website at www.atreca.com.

What is the stock symbol for Atreca, Inc.?

Atreca, Inc. is traded under the stock symbol BCEL on NASDAQ.